Intracoronary thrombus in ST-segment elevation myocardial infarction: Practical management strategies for the

Debabrata Dash1, Umanshi Dash2, Rohit Mody2

  • 1Department of Cardiology, Aster Hospital, Dubai, United Arab Emirates.

Indian Heart Journal
|June 10, 2026
PubMed

Insights

Managing intracoronary thrombus in ST-segment elevation myocardial infarction (STEMI) requires personalized strategies. This review details pharmacological and mechanical approaches for optimal primary percutaneous coronary intervention (PPCI) outcomes.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Acute Coronary Syndromes

Background:

  • Intracoronary thrombus is a key feature of STEMI, complicating PPCI and leading to adverse outcomes like microvascular obstruction and stent thrombosis.
  • Effective management necessitates a tailored approach combining pharmacologic and mechanical interventions.

Purpose of the Study:

  • To review the pathophysiology, assessment, and clinical impact of intracoronary thrombus in STEMI.
  • To discuss current and emerging therapies, including pharmacological agents and mechanical devices.
  • To propose a management algorithm for interventional cardiologists.

Main Methods:

  • Narrative review of intracoronary thrombus management in STEMI during PPCI.
  • Literature search of PubMed and Embase (2000-2026), including guidelines and society recommendations.
  • Qualitative synthesis of evidence from RCTs, observational studies, meta-analyses, and guidelines.

Main Results:

  • Intracoronary thrombus in STEMI presents significant challenges during PPCI, impacting reperfusion and clinical outcomes.
  • A combination of pharmacologic therapies (dual antiplatelet therapy, anticoagulation, GP IIb/IIIa inhibitors, thrombolytics) and mechanical strategies (thrombectomy, stenting) is crucial.
  • Evidence from trials and guidelines supports individualized treatment based on thrombus burden and lesion characteristics.

Conclusions:

  • Optimal management of intracoronary thrombus in STEMI involves an individualized, stepwise approach integrating pharmacologic and mechanical strategies.
  • A proposed algorithm assists clinicians in tailoring therapy for improved PPCI outcomes.
  • Emerging technologies hold promise for enhanced thrombus management and microvascular reperfusion.

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...